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Background
The laboratory diagnosis of hereditary spherocytosis commonly relies on NaCl-based or glyc-
erol-based red cell osmotic fragility tests; more recently, an assay directly targeting the heredi-
tary spherocytosis molecular defect (eosin-5’-maleimide-binding test) has been proposed. None
of the available tests identifies all cases of hereditary spherocytosis.
Design and Methods
We compared the performances of the eosin-5’-maleimide-binding test, NaCl-osmotic fragility
studies on fresh and incubated blood, the glycerol lysis test, the acidified glycerol lysis test, and
the Pink test on a series of 150 patients with hereditary spherocytosis grouped according to clin-
ical phenotype and the defective protein, with the final aim of finding the combination of tests
associated with the highest diagnostic power, even in the mildest cases of hereditary spherocy-
tosis.
Results
The eosin-5’-maleimide-binding test had a sensitivity of 93% and a specificity of 98% for
detecting hereditary spherocytosis: the sensitivity was independent of the type and amount of
molecular defect and of the clinical phenotype. The acidified glycerol lysis test and Pink test
showed comparable sensitivity (95% and 91%) . The sensitivity of NaCl osmotic fragility tests,
commonly considered the gold standard for the diagnosis of hereditary spherocytosis, was 68%
on fresh blood and 81% on incubated blood, and further decreased in compensated cases (53%
and 64%, respectively). The combination of the eosin-5’-maleimide-binding test and acidified
glycerol lysis test enabled all patients with hereditary spherocytosis to be identified. The eosin-
5’-maleimide-binding test showed the greatest disease specificity.
Conclusions
Each type of test fails to diagnose some cases of hereditary spherocytosis. The association of an
eosin-5’-maleimide-binding test and an acidified glycerol lysis test enabled identification of all
patients with hereditary spherocytosis in this series and, therefore, represents a currently effec-
tive diagnostic strategy for hereditary spherocytosis including mild/compensated cases.
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ABSTRACT
Introduction
Hereditary spherocytosis is the most common congeni-
tal hemolytic anemia in Caucasians, affecting approxi-
mately 1 in 1000-2000 individuals.1,2 The molecular defect
is highly heterogeneous involving the genes encoding for
spectrin, ankyrin, band 3 and protein 4.2,3 and the degree
of hemolysis varies widely, from fully compensated to
transfusion-dependent anemia. 
The typical laboratory hallmark of hereditary spherocy-
tosis, although not specific, is the presence of spherocytes
on a peripheral blood smear, which are detectable in 97%
of patients.4 However, there may be very few spherocytes
in some patients4,5 and skilled operators are, therefore, nec-
essary to detect them; moreover, microscopic examination
of red cells is increasingly omitted in the era of laboratory
automation. The laboratory diagnosis of hereditary sphero-
cytosis does, therefore, commonly rely on tests that exploit
the surface area-to-volume ratio, typically reduced in spher-
ical erythrocytes, in particular red cell osmotic fragility tests
at various sodium chloride (NaCl) concentrations on fresh
and incubated blood,6 and assays that measure the extent
or the rate of lysis of red cells suspended in  buffered glyc-
erol solutions, i.e. the glycerol lysis test (GLT),7 the acidified
glycerol lysis test (AGLT)8 and the Pink test.9 However,
these tests do not pick up a variable proportion of cases of
hereditary spherocytosis, particularly the mildest ones,6,10-12
and do not differentiate hereditary spherocytosis from sec-
ondary spherocytosis associated with other conditions,
mainly autoimmune hemolytic anemias.13-15
More recently, the cryohemolysis test,16,17 based on the
observation  that red cells from patients with hereditary
spherocytosis are particularly susceptible to cooling at 0°
C in hypertonic conditions, and the flow cytometric
analysis of eosin-5’-maleimide-labeled intact red blood
cells (EMA-binding test)18 have been proposed as new
methods for identifying hereditary spherocytosis.19 The
latter in particular has been proven to be a sensitive and
specific diagnostic test for hereditary spherocytosis12,18,20-29
directly targeting the structural lesion of this disease, since
the fluorescent probe, eosin-5’-maleimide, interacts with
the  protein band 3 complex.30
The performance of the available direct or indirect diag-
nostic tests has been mostly evaluated individually and on
limited number of cases. The sensitivity of the test varies
greatly and each method fails to identify several patients
with hereditary spherocytosis.4,6,12 In this study, we com-
pared the performances of EMA-binding, NaCl-induced
osmotic fragility of fresh and incubated blood, GLT, AGLT
and Pink tests on a series of 150 patients with hereditary
spherocytosis grouped according to the clinical phenotype
and molecular lesion, with the final aim of finding the
combination of tests associated with the highest diagnos-
tic power for hereditary spherocytosis, including the
mildest cases which are usually difficult to diagnose.
Design and Methods
Subjects
One hundred and fifty consecutive patients with hereditary
spherocytosis (79 males and 71 females, median age 26 years,
range 0-79 years) belonging to 128 unrelated families were inves-
tigated. At the time of the study, 22 patients were splenectomized
and 128 not splenectomized. 
All patients underwent clinical and physical evaluation and the
following laboratory tests: complete blood counts, blood smear
examination, reticulocyte count, assays of bilirubin and haptoglo-
bin concentration, assessment of iron status, direct antiglobulin
test (DAT), screening for abnormal or unstable hemoglobins, NaCl
osmotic fragility test on fresh and incubated blood, GLT, AGLT,
Pink test and EMA-binding test. In some cases, the activity of the
most important glycolytic and pentose phosphate pathway
enzymes was investigated. In a few patients, the mitogen-stimu-
lated DAT31 was also performed to rule out the diagnosis of DAT-
negative hemolytic anemia.
Hereditary spherocytosis was diagnosed on the basis of  clinical
and laboratory signs of chronic hemolysis, presence of sphero-
cytes at peripheral blood smear examination, positivity of at least
one red cell fragility test, family history of hereditary spherocyto-
sis if any, and exclusion of other causes of secondary spherocyto-
sis.19 Anemia was defined as severe (Hb<8 g/dL), moderate (Hb 8-
10 g/dL), mild (Hb>10 and <11.5 g/dL for females and Hb>10 and
<13.5 g/dL for males) and compensated (Hb>11.5 g/dL for females
and >13.5 g/dL for males).  
Samples from all patients were subjected to sodium dodecylsul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) for analysis of
the red cell membrane proteins and divided according to whether
there was deficiency of band 3, spectrin or ankyrin, combined
spectrin/ankyrin deficiency, and no detectable defect.4
Five hundred and seventy-five healthy blood donors and 84
cases with hemolytic anemia other than hereditary spherocytosis
(17 with autoimmune hemolytic anemia, 10 with red cell enzyme
disorders, 10 with hereditary elliptocytosis, 15 with congenital
dyserythropoietic anemia, 9 with paroxysmal nocturnal hemoglo-
binuria, 3 with stomatocytosis, 3 with mechanical anemia, and 17
with anemia of unknown cause) were also studied.
Hematologic assays
Peripheral blood was collected from patients and controls dur-
ing diagnostic procedures after obtaining informed consent and
approval from the Institutional Human Research Committee. The
procedures followed were in accordance with the Helsinki inter-
national ethical standards on human experimentation. The great
majority of samples were collected in our institute; samples col-
lected from other centers were shipped maintaining a temperature
of 4°C and always processed within 24 h. All tests were per-
formed in a single site. None of the patients had been transfused
within the 3 months preceding the study. Hematologic parameters
were determined on an automated hematology analyzer
(Automatic Beckman Coulter LH-750, CA, USA).  Routine hema-
tologic investigations were carried out according to Dacie &
Lewis.32 Bilirubin, haptoglobin, and ferritin levels were determined
using Integra 800 (Roche, Mannheim, Germany). The number of
spherocytes in peripheral blood was assessed by two independent
and expert operators. Red cell osmotic fragility was evaluated by
performing the NaCl osmotic fragility test on both fresh and incu-
bated blood,6 the standard GLT,7 the AGLT8 and the Pink test9 on
samples from each patient.
The EMA-binding test was performed as described by King et
al.18 with minor modifications. In particular, fluorescence inten-
sity, expressed as median channel fluorescence, was determined
for 10,000 events in the FL-1 channel, using a Becton Dickinson
FACSCanto II flow cytometer (Becton Dickinson, San Jose, CA,
USA).  The EMA dye stock solution was stored in small aliquots
at -80° C over a period of 6 months. The test was performed
once a week grouping all cases in the same day25 after confirm-
ing the reproducibility of results on blood samples stored up to
6 days at 4°C.
In order to decrease intra-assay variation, patients’ samples
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were compared with those of six normal controls. Results were
expressed as the percentage of fluorescence reduction of the
patient’s sample compared to the mean fluorescence of the six
normal controls as proposed by Girodon et al.25 A receiver oper-
ating characteristic (ROC) curve based on logistic regression
analysis was used to determine the optimum cut-off between
values from patients with hereditary spherocytosis and those
from normal individuals. According to the ROC curve analysis,
the optimum decrease in fluorescence to separate normal sub-
jects from patients with hereditary spherocytosis was 11%. In
these conditions test specificity computed on 575 healthy sub-
jects was 98%.
Red cell ghosts were prepared within 24 h of blood collection
using the method described by Dodge et al.33 with slight modifica-
tions.4 Red cell membrane proteins were analyzed within 15 days
of ghost preparation by SDS-PAGE using a 4% to 12% gradient of
acrylamide according to Fairbanks et al.34 and the discontinuous
buffer system of Laemmli35 with an acrylamide linear gradient
from 6% to 14%, as previously described.4 Activities of enzymes
of the glycolytic and pentose phosphate pathways were assayed
using the methods described by Beutler.36 
Results 
Table 1 shows the hematologic and biochemical data of
the patients with hereditary spherocytosis grouped
according to whether they had not been splenectomized
or had been splenectomized before the time of the study,
and according to the clinical phenotype (in non-splenec-
tomized patients only). The majority of non-splenec-
tomized subjects had mild to compensated hemolysis;
18% had very few spherocytes (≤3%). The most common
protein abnormalities were spectrin and band 3 deficien-
cies in both non-splenectomized and splenectomized
patients. The membrane protein defect was undetectable
in nine (7%) non-splenectomized subjects, seven of whom
had a positive family history of hereditary spherocytosis;
the remaining two displayed mild anemia, reticulocytosis
and 5% spherocytes, in the absence of other causes of
chronic hemolytic anemia.
Table 2 compares the sensitivity of the diagnostic labo-
ratory tests for hereditary spherocytosis. EMA-binding
failed to identify 10/150 (7%) cases (4 with band 3 defi-
ciency, 5 with spectrin deficiency and 1 with an undetect-
ed defect). The mean decrease in fluorescence was 27% ±
10% in patients with hereditary spherocytosis versus 0 %
± 8% in reference subjects (P<0.001). The percent fluores-
cence reduction was directly related to the number of
spherocytes and indirectly with the mean corpuscular vol-
ume; no correlation was found with hemoglobin concen-
tration, absolute number of reticulocytes or red cell distri-
bution width. The test’s sensitivity was independent of
the type and amount of molecular defect, although it was
slightly lower in patients with undetected defects who
had the smallest median decrease in fluorescence (15%
versus 30% and 28% in band 3 and spectrin deficiency,
respectively). It is worth noting that the sensitivity of the
EMA-binding test was slightly higher in splenectomized
than in non-splenectomized patients (Figure 1). 
The sensitivity of the various red cell fragility assays
investigated was very variable and generally higher in
splenectomized than in non-splenectomized hereditary
spherocytosis, and lower (with the exception of AGLT) in
the patients with undetected defects than in those with
detectable defects (Table 2A). As regards the NaCl osmotic
fragility test, the sensitivity was greater when performed
on incubated blood than on fresh blood. Overall, NaCl
osmotic fragility tests (both on fresh and incubated blood)
had a lower sensitivity than the more commonly used
glycerol-based tests. Among these latter assays, AGLT had
the highest sensitivity, also in the cases with undetected
defects, comparable to that of the EMA-binding test.
All patients with hereditary spherocytosis were positive
to at least two different tests with the exception of two
patients (1 with band 3 deficiency and 1 with spectrin
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Table 1. Hematologic and biochemical data of patients with hereditary spherocytosis grouped according to whether they had or had not been
splenectomized.
Not splenectomized Splenectomized
(n=128) (n=22)
Severe to moderate Mild anemia Compensated All (n=128)
anemia (n= 32 ) (n=48) anemia (n=48)
Hematologic parametersa
Hemoglobin (g/dL) 9 (5.5-10) 11.3 (10.2-13) 13.8 (11.7-16.2) 11.4 (5.5-16.2) 14.9 (11.2-18.8)
Mean cell volume (fL) 77 (65.6-105) 84 (62.5-105) 88 (83-104) 85.5 (62.5-123) 87 (82.1-96.8)
MCHC (g/dL) 33.25 (31.4-37.7) 35.25 (30.4-38.3) 35.3 (27.9-37.7) 34.8 (27.9-38.4) 35.5 (31.5-37.1)
Spherocytes (%) 8 (1-28) 7 (1-23) 9 (1-43) 8 (1-43) 8 (2-60)
Reticulocytes (¥109/L) 40 (52-463) 252 (19-579) 180 (34-512) 222 (19-579) 116.5 (41-415)
Unc. bilirubin (mg/dL) 2.3 (0.1-22.2) 1.75 (0.4-9.23) 2.6 (0.5-9.9) 2.5 (0.1-22.2) 0.71 (0.24-4.7)
Defective proteinb
Band 3 11 23 17 51 8
Spectrin 16 21 25 62 11
Combined spectrin-ankyrin 4 0 2 6 3
Undetected 1 4 4 9 0
amedian values (range); bnumber of cases; MCHC: mean cell hemoglobin concentration; Unc.: unconjugated.
deficiency) who were positive only in the EMA-binding
test. We found that the combination of EMA and AGLT
enabled identification of all the patients with hereditary
spherocytosis (Table 2B). In particular, 133/150 (88%) of
hereditary spherocytosis cases were EMA-positive, AGLT-
positive, 7/150 (5%) were EMA-positive, AGLT-negative
and  10/150 (7%) were EMA-negative, AGLT-positive. 
When the performance of the various tests was ana-
lyzed in non-splenectomized patients as a function of the
clinical phenotype, EMA-binding, the AGLT and the Pink
test maintained high sensitivity in the different clinical
subsets, whereas the sensitivity of the NaCl osmotic
fragility test on fresh blood and after incubation dropped
markedly in compensated cases (Figure 1).
The results of various tests in a series of 84 patients with
hemolytic conditions other than hereditary spherocytosis
are depicted in Figure 2. EMA-binding showed the greater
disease specificity being negative in all patients with
autoimmune hemolytic anemia, even in the presence of
marked spherocytosis.
Discussion
This is the first extensive comparison study of the most
currently used laboratory methods for diagnosing heredi-
tary spherocytosis, carried out on a large number of
patients grouped according to the molecular defect, the
degree of hemolysis and the presence or absence of the
spleen. The finding that half of the examined patients had
mild/compensated anemia and were, therefore, more dif-
ficult to diagnose, and that 18% had very few spherocytes
on peripheral blood smear, makes the population exam-
ined particularly suitable for sensitivity studies. We did
not include the  cryohemolysis test17 in this study since the
basis of the susceptibility of hereditary spherocytosis red
blood cells to cooling has not been elucidated so far,  and
opinions on its routine utilization for the diagnosis of
hereditary spherocytosis are controversial.4,5,16,17,19,37,38 
Among the diagnostic methods considered, the recently
proposed EMA-binding test is certainly the most interest-
ing one, and it is being increasingly used by specialized
laboratories because of its high sensitivity and specifici-
ty.12,18,23-29 This method directly targets the structural lesion
of the disease, since the fluorescent probe eosin-5’-
maleimide interacts with transmembrane proteins band 3,
Rh protein, Rh glycoprotein and CD47 which are reduced
in red cells from patients with hereditary spherocytosis;30
defects of other cytoskeletal proteins, such as spectrin and
protein 4.2, also induce a decrease in fluorescence intensi-
ty, likely because they create a long-range modulation
effect on the dye binding site in band 3 protein.39 The sen-
sitivity of the EMA-binding test in this series is higher
than that recently reported by Crisp et al.,12 and similar to
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Table 2. (A) Sensitivity of single tests in patients with hereditary spherocytosis (HS) grouped according to the biochemical defect. (B) The sensi-
tivity of combined tests in total HS cases. The number represents the ratio of  positive cases/total cases with percent values in brackets. 
A
EMA-binding GLT AGLT Pink OF (NaCl fresh) OF (NaCl inc.)
Total HS patients 140/150 (93%) 92/150 (61%) 143/150 (95%) 136/150 (91%) 102/150 (68%) 122/150 (81%)
HS with biochemical defect  132/141 (94%) 90/141 (64%) 135/141 (96%) 131/141 (93%) 100/141 (71%) 119/141 (84%)
Spectrin 68/73 (93%) 45/73 (61%) 70/73 (96%) 67/73 (92%) 51/73 (70%)      62/73 (85%)
Band 3 55/59 (93%) 38/59 (64%) 56/59 (93%) 55/59 (93%) 43/59 (73%)     49/59 (83%)
Combined spectrin/ankyrin 9/9 (100%) 7/9 (78%) 9/9 (100%) 9/9 (100%) 6/9 (67%)    8/9 (89%)
HS with undetectable defect 8/9 (88%) 2/9 (22%) 8/9 (88%) 2/9 (22%) 3/9 (33%) 4/9 (44%)
B
EMA + AGLT EMA + OF (NaCl fresh) EMA + OF (NaCl inc.) EMA + Pink OF (NaCl inc.) + AGLT
Total HS patients 150/150 (100%) 143/150 (95%) 143/150 (95%)  149/150 (99%) 146/150 (97%)
OF: osmotic fragility; Inc.: incubated.
Figure 1. Sensitivity of various diagnos-
tic tests in 22 splenectomized and 128
not splenectomized patients with hered-
itary spherocytosis (HS). Non-splenec-
tomised patients with HS were divided
according to clinical phenotype.
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that found by others;18,23-29 moreover, the test’s perform-
ance appears to be independent of the type of red cell
membrane protein deficiency, and decreases only slightly
in hereditary spherocytosis patients with an undetectable
defect, in line with what was observed by King et al.,18 and
Girodon et al.25 Interestingly, sensitivity is independent of
clinical phenotype, being high also in patients with com-
pensated anemia. The separate analysis of non-splenec-
tomized and splenectomized patients with hereditary
spherocytosis showed that sensitivity increased in the lat-
ter group, a finding generally common to all the tests
investigated; this observation pinpoints the need to define
the clinical characteristics of patients precisely when test-
ing the performance of diagnostic methods for hereditary
spherocytosis, and possibly to limit the analysis to non-
splenectomized subjects. A further advantage of the EMA-
binding test is that results are not influenced by shipping
or storage for up to 6 days, as shown in Figure 3, thus
enabling shipping of samples as reported by Girodon et
al.25 Moreover, results are not affected by recent transfu-
sions since the method discriminates different red cell
populations.20
As regards the NaCl osmotic fragility tests, we found
that these failed to identify nearly a quarter of patients
with hereditary spherocytosis, confirming results from
other researchers,12,13,19,40,41 and that their sensitivity was
generally lower than that of the other diagnostic laborato-
ry tests evaluated in this series. In spite of this, incubated
NaCl osmotic fragility is still commonly considered the
gold standard for diagnosing hereditary spherocytosis in
patients with Coombs’-negative hemolytic anemias.5,11,42
Indeed, the analysis of the literature reveals that no sys-
tematic studies on sensitivity of this test have been per-
formed in the past, and that the assertion that it is the best
method for the diagnosis of hereditary spherocytosis is
based on studies carried out on limited numbers of
patients with not clearly defined clinical characteristics;
moreover, the interpretation of the NaCl osmotic fragility
curves may be difficult in less typical cases.8 The high
number of patients considered in this series enabled us to
correlate the performance of the NaCl osmotic fragility
test with the clinical expression of the disease: the obser-
vation that in cases of compensated hereditary spherocy-
tosis the sensitivity of osmotic fragility tests decreased to
nearly 60%, much more than reported by Korones &
Pearson,13 further limits the utility of this method in the
mildest and less typical cases. This is also confirmed by
the finding that the sensitivity drops to 30% in patients
P. Bianchi et al.
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Figure 2. Results of individual diagnostic tests in patients with hemolytic anemias other than hereditary spherocytosis (HS), compared with
those with HS. The shaded area represents normal reference intervals. CDA: congenital dyserythropoietic anemia; AIHA: autoimmune
hemolytic anemia; HE: hereditary elliptocytosis; PNH: paroxysmal noctural hemoglobinuria
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with hereditary spherocytosis with an undetectable bio-
chemical defect. 
The glycerol-based red cell fragility tests, with the
exception of the original version GLT, are more sensitive
than the NaCl osmotic fragility test; in particular, in this
series, the AGLT had a sensitivity of 95%, similar to that
found by others1,15,43,44 and higher than that reported by
Cynober et al.10 and Bucx et al.45 The sensitivity of the
AGLT was also high in compensated cases and in those
with an undetected biochemical defect. Moreover, it is
worth noting that the AGLT identified the ten EMA-nega-
tive cases of hereditary spherocytosis. 
The association of EMA-binding and the AGLT enabled
identification of all the cases of hereditary spherocytosis in
this series; since flow cytometer is not available in all diag-
nostic laboratories, it is worth mentioning that the AGLT
plus the NaCl osmotic fragility test on incubated blood
raises the diagnostic sensitivity to 97%, similar to that pre-
viously reported in a larger series of patients4: in any cases,
this value is higher than that obtained by combining
EMA-binding and the cryohemolysis test, as recently
reported by Crisp et al.12
The disease specificity of the diagnostic tests for hered-
itary spherocytosis was evaluated by including a large
group of patients with different types of hemolytic ane-
mia that may show morphological and laboratory features
similar to those of hereditary spherocytosis. As expected,
the results of EMA-binding, in terms of percent fluores-
cence reduction, were directly related to the number of
spherocytes only in patients with hereditary spherocyto-
sis, but not in patients with autoimmune hemolytic ane-
mia, even in those with marked spherocytosis: this obser-
vation is in line with the high disease specificity of this
test reported by others.19-21,25 We found that the other
assays, in particular the glycerol-based ones, are less spe-
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Figure 3. (A) Mean channel fluorescence values in normal controls
and patients with hereditary spherocytosis (HS) at different days of
storage. (B-C) Results of EMA-binding test in samples  from 150 HS
patients grouped  according to shipping (B) and  days of  storage
before testing (C). n Controls, l HS not shipped, m HS shipped.
Figure 4. Flow chart for laboratory diagnosis of hereditary spherocytosis (HS).
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cific than EMA-binding, since, as reported previous-
ly,8,9,14,15,46 they are often positive also in acquired hemolytic
anemias. It is worth mentioning that none of the available
diagnostic tests for hereditary spherocytosis, whether
direct or indirect, differentiates hereditary spherocytosis
from congenital dyserythropoietic anemia type II. This lat-
ter disorder, although less prevalent than hereditary sphe-
rocytosis, may mimic the clinical presentation, red cell
morphology and increased red cell osmotic fragility of
hereditary spherocytosis and may require SDS-PAGE
analysis to be identified: Mariani et al. reported that 13%
of cases referred to a reference laboratory with the provi-
sional label of hereditary spherocytosis were found to be
congenital dyserythropoietic anemia type II when exam-
ined by SDS-PAGE.47
The diagnostic guidelines for hereditary spherocytosis
from the British Committee for Standards in
Hematology,19 the only so far available, recommend either
EMA-binding or the cryohemolysis  test as a screening
method,16 the deciding factor for the choice being the
availability of a flow cytometer. The guidelines do not
specify whether, in the case of equivocal or borderline
results, both tests should be performed. In any case, even
the association of these two tests gives a sensitivity of
93%, similar to that of EMA-binding or AGLT used alone,
and much lower than that obtained by the combination of
EMA-binding plus AGLT.
As seen in Figure 4, in the presence of a patient with
DAT-negative chronic hemolysis with spherocytes, the
negativity of both EMA and AGLT enables hereditary
spherocytosis to be excluded. Positivity of EMA-binding
(with either a positive or negative AGLT) leads to the diag-
nosis of hereditary spherocytosis except in those non-
dominant cases with inadequate reticulocytosis11 which
need SDS-PAGE analysis to exclude congenital dysery-
thropoietic anemia type II.  SDS-PAGE analysis may also
be required in the rare EMA-negative, AGLT-poistive
cases with  a negative family history, due to the lesser dis-
ease specificity of AGLT. 
In conclusion, no single test is able to identify all cases
of hereditary spherocytosis. The association of EMA-
binding, which directly targets the structural defect of
hereditary spherocytosis, and AGLT, which exploits the
red cell surface area-to-volume ratio, allowed us to identi-
fy all the patients with hereditary spherocytosis in this
series and, therefore, represents a very effective diagnostic
strategy for hereditary spherocytosis also in mild/compen-
sated cases.  However, it must be underlined that the diag-
nosis of hereditary spherocytosis is the final step of a diag-
nostic work-up based not only on laboratory tests but also
on clinical examination, personal family history, and the
exclusion of possible causes of secondary spherocytosis. 
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